Selin Bolca
Seminars
Wednesday 17th March 2027
Targeting Pathogenic IgA Biology in IgAN to Test a First-in-Class Mechanism & Build Confidence for Late- Stage Development
12:30 pm
- Evaluating ARGX-121 in the Phase II VERDANT study as a first-in-class IgA-targeting therapy to intervene directly in disease-driving immune biology, testing whether a more upstream mechanism can deliver differentiated benefit in an increasingly competitive IgAN landscape
- Using a randomized, placebo-controlled design in approximately 120 adults with primary IgAN, with change in proteinuria at Week 24 as the primary outcome to generate an early efficacy signal, supporting faster go/no-go decisions before committing to larger registrational studies
- Following patients through up to 52 weeks of ARGX-121 treatment while assessing renal function, pharmacokinetics and immune response to connect short-term proteinuria effects with broader biological and clinical readouts, strengthening confidence in mechanism, durability and Phase III development strategy
